ITCI (Intra-Cellular Therapies) Net Financial Result

ITCI (Intra-Cellular Therapies) - company brandmark

The growth of Intra-Cellular Therapies (ITCI) relies on insurance coverage for therapy and the expansion of the list of diagnoses. High confidence among psychiatrists in the Caplyta brand has solidified the company's status as an innovative leader in the treatment of schizophrenia. The firm's net income on the GURU.Markets platform chart, where -0.07 records a new level mark, confirms the stability of the business while fully retaining its staff of leading neurobiologists.

ITCI - intracellulartherapies.com Net Income over the range 07/04/2022 - 04/13/2025

Financial and market metric breakdowns for intracellulartherapies.com (ITCI)

- stock value and consensus price forecast:
Market Price Intra-Cellular Therapies, Inc.|ITCI - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Intra-Cellular Therapies, Inc.|ITCI - Total Company Value
- shareholders' equity book value data:
Equity per Share Intra-Cellular Therapies|ITCI - Company Net Assets|Market Cap to Book Value Multiple intracellulartherapies.com|ITCI - Aggregate Company Assets
- debt and liquidity details:
All Debt to Shareholders' Equity Ratio Intra-Cellular Therapies|ITCI - Long-Term Debt to Capital|Short-Term Debt to Capital Intra-Cellular Therapies, Inc.|ITCI - Company Total Debt|Debt to Net Assets Intra-Cellular Therapies, Inc.|ITCI - Company Long-Term Debts|Company Current Liabilities Intra-Cellular Therapies|Immediate Liquidity intracellulartherapies.com
- earnings and market ratios statistics:
ITCI - Company Net Income
Summary company analysis:ITCI (Intra-Cellular)
Manufactured products of intracellulartherapies.com

This indicator aggregates actual cash inflows minus all operating expenses, allowing for a real-time assessment of financial results without the delays of quarterly reporting. Analyzing the net operating profit of Intra-Cellular Therapies (ITCI) helps evaluate the stability of Intra-Cellular Therapies, where steady demand for chronic disorder therapies should ensure predictable capital growth and minimize the risk of cash flow gaps.

Direct competitors

Company Net Income Biogen Idec (BIIB)|NBIX (Neurocrine Biosciences) - Net Profit|regencellbioscience.com (RGC) - Net Financial Result|Company Net Income Axsome Therapeutics, Inc. (AXSM)|ACADIA Pharma - Company Profit|Xenon Pharmaceuticals Inc - Net Income|Profit After Payment of Taxes VKTX (Viking Therapeutics Corp)|SUPN - Company Net Income|Final Profit CPRX (catalystpharma.com)|DNLI: Net Profit|Harmony Biosciences Inc (HRMY) - Net Profit|Net Income BHVN|AMLX - Annual Net Income|Net Profit TRVI|Net Income praxismedicines.com PRAX|Net Profit AVXL (Anavex Life Sciences Corp.)|CeriBell Inc (CBLL) - Company Net Income|PRTA - Company Net Income|ALEC: Company Net Income|Annexon, Inc. (ANNX) - Company Net Income|OMER (Omeros) - Company Net Income|Net Income NGNE|Net Profit AC Immune S.A.|Company Net Income Voyager Pharma (VYGR)|Company Net Income NMRA (Neumora Corp)|Net Profit SCLX (Scilex Holding Company)|Net Profit tevogen.com TVGN|ACOG - Company Net Income|Final Profit CGTX (cogrx.com)|IKT (Inhibikase) - Net Income|Cassava Pharma - Final Profit|Net Income ASRT|COYA (Coya) - Profit After Payment of Taxes|Net Profit VTGN|OVID (ovidrx.com) - Final Profit|Net Profit ABOS (Acumen Pharma)|CervoMed Corporation (CRVO) - Company Net Income|ATHE - Company Net Income|Final Profit CLNN (Clene Inc.)|PEPG: Net Profit|jupiterneurosciences.com (JUNS) - Net Profit|Company Net Income Relmada|Annovis Bio Corporation - Profit After Tax|Net Profit GRCE|Net Financial Result fireflyneuro.com|Net Profit KLTO (Klotho Neurosciences)|NeuroSense Therapeutics Ltd (NRSN) - Company Net Income|RVPH - Company Net Income|Net Financial Result MetaVia Inc MTVA|NRXS: Net Profit|HSDT - Net Financial Result|Net Income PASG|NEUP (Neuphoria) - Profit After Payment of Taxes|Net Profit NERV|Net Income Athira Pharma Corp ATHA|Net Profit ADXN (Addex Therapeutics)|Net Financial Result Alzamend Neuro Inc. (ALZN)|CYCN - Company Net Income|PTIX (Protagenic Therapeutics) - Company Profit|KTTA: Net Profit|Company Net Income Cortigent (CRGT)|Net Income ATXI|Net Profit brainstorm-cell.com|Company Net Income Cara Therapeutics (CARA)|CHRO (Chromocell Therapeutics Corp) - Final Profit|Company Net Income Eliem Therapeutics Inc. ELYM|Longboard (LBPH) - Company Net Income|Marinus Pharmaceuticals - Net Profit|Net Financial Result nkgenbiotech.com NKGN|NeuroBo Pharmaceuticals, Inc. (NRBO) - Company Net Income|Company Profit SAGE|Net Income SNPX|TRVN (Trevena Inc) - Profit After Payment of Taxes|Company Net Income Vigil Neuroscience (VIGL)|WENA (Anew Medical Inc.) - Final Profit|Net Profit CERE (Cerevel Therapeutics, Inc.)